首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1620197

糖尿病足潰瘍的全球市場規模：按治療類型、設備、最終用戶和地區劃分

Global Diabetic Foot Ulcers Market Size By Type of Treatment, By Devices, By End-users, And By Geography

出版日期: 2024年08月25日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

糖尿病足潰瘍市場規模及預測

2023 年糖尿病足潰瘍市場規模為 15.3 億美元，預計到 2030 年將達到 31 億美元，預計 2024-2031 年複合年增長率為 9.24%。

糖尿病足潰瘍的全球市場推動因素

糖尿病足潰瘍市場的市場推動因素可能受到多種因素的影響。

糖尿病盛行率增加：

隨著全球糖尿病盛行率的增加，糖尿病足潰瘍的盛行率也在增加。由於糖尿病患者人數不斷增加以及足部潰瘍等併發症的風險增加，對糖尿病的治療和管理方法的需求不斷增長。

人口老化：

糖尿病及其後果（例如糖尿病足潰瘍）在老年族群中更為常見。隨著人口老化，面臨 DFU 風險的人數增加，這是市場擴張的驅動力。

技術進步：

隨著傷口治療技術的進步，包括改進的敷料、負壓傷口治療和生物工程皮膚替代品，糖尿病足潰瘍的治療和結果正在改善。這些技術的採用降低了截肢風險並提高了治癒率，從而推動了市場擴張。

政府計畫：

DFU 市場主要由政府旨在減輕糖尿病及其併發症負擔的計劃推動。隨著政策強調糖尿病教育、預防和獲得醫療保健服務，對 DFU 治療的需求可能會增加。

醫療支出增加：

醫療保健支出的增加將有可能改善糖尿病足潰瘍的治療和管理方案，特別是在新興國家。隨著越來越多的人和醫療機構投入資源來控製糖尿病及其影響，DFU 市場將會成長。

意識計畫：

透過教育人們足部護理對糖尿病患者的重要性，醫療機構、患者權益團體和製藥公司可以鼓勵足部潰瘍的早期發現和治療，這將對市場產生積極影響。糖尿病足潰瘍可導致感染和下肢截肢等嚴重併發症，進而導致巨大的醫療費用和經濟壓力。透過有效的管理和治療計劃來解決這些問題已變得至關重要，從而增加了對 DFU 產品和服務的需求。

聯合研發：

製藥公司、學術機構和醫療保健提供者之間的合作正在開發糖尿病足潰瘍的新治療方法和乾預措施。這些合作關係加快了研發步伐，從而推出了新穎的產品和治療方法並擴大了市場。

限制全球糖尿病足潰瘍市場的因素

有幾個因素可能會成為糖尿病足潰瘍市場的限制和課題。其中包括：

治療費用高：

糖尿病足潰瘍的治療費用可能很高，因為需要持續就診、使用專業傷口護理產品，有時還需要手術。患者可能會發現自己陷入財務困難，特別是如果他們的醫療保險有限。

醫療基礎設施不足：

許多地區，特別是貧窮國家，沒有足夠的醫療保健基礎設施或接受過糖尿病足潰瘍管理培訓的合格衛生工作者。這可能導致診斷延遲、治療不充分和患者預後不良。

病人依從性差：

成功治療糖尿病足潰瘍通常需要嚴格遵守治療方案，包括傷口護理、血糖控制和生活方式調整。然而，由於各種原因，包括無知、經濟問題和心理障礙，某些患者可能難以堅持治療。

糖尿病盛行率增加：

糖尿病在世界各地變得越來越普遍，增加了糖尿病足潰瘍的風險。這給醫療保健系統帶來了沉重負擔，加劇了資源短缺，並增加了治療糖尿病足潰瘍的需求。

併發症

下肢截肢、壞疽和感染是糖尿病足潰瘍可能導致的一些嚴重後果。這些問題不僅增加醫療費用，而且對患者的生活品質產生重大負面影響。

監理課題：

冗長且昂貴的監管審批程序可能會阻礙糖尿病足潰瘍新療法的開發和商業化。對於希望將新療法推向市場的公司來說，嚴格的監管可能是一個問題。

競爭環境：

在競爭激烈的糖尿病足潰瘍市場中，許多公司提供各種產品和治療方法。來自競爭對手的價格競爭會降低利潤率和定價能力，特別是對於提供新療法的公司而言。

Diabetic Foot Ulcers Market size was valued at USD 1.53 Billion in 2023 and is projected to reach USD 3.1 Billion by 2030 , growing at a CAGR of 9.24% during the forecast period 2024-2031. Global Diabetic Foot Ulcers Market Market Drivers The market drivers for the Diabetic Foot Ulcers Market can be influenced by various factors. These may include: Growing Prevalence of Diabetes:

As the incidence of diabetes rises worldwide, so does the prevalence of diabetic foot ulcers. The need for therapies and management alternatives for diabetes is fueled by the growing number of people with the disease and the increased risk of complications such foot ulcers.

Aging Population:

Diabetes and its consequences, such as diabetic foot ulcers, are more common in the aging population. The number of individuals at risk of DFUs rises with population aging, which fuels market expansion.

Technological Advancements:

The management and results of treatment for diabetic foot ulcers are being improved by advances in wound care technology, such as improved dressings, negative pressure wound therapy, and bioengineered skin substitutes. Adoption of these technologies lowers the risk of amputations and improves healing rates, which propels market expansion.

Governmental Programs:

The DFU market is mostly driven by government programs focused at lowering the burden of diabetes and its comorbidities. The need for DFU therapies may rise in response to policies that emphasize diabetes education, prevention, and healthcare service accessibility.

Growing Healthcare Expenditure:

More access to diabetic foot ulcer therapies and management choices is made possible by rising healthcare spending, especially in emerging economies. The DFU market grows as more people and healthcare institutions devote resources to controlling diabetes and its consequences.

Awareness Programs:

By educating people on the value of foot care for diabetic patients, healthcare organizations, patient advocacy groups, and pharmaceutical companies can encourage early detection and treatment of foot ulcers, which will have a beneficial effect on the market. Diabetic foot ulcers can result in serious complications such infections and lower limb amputations, which can lead to significant healthcare costs and financial stress. It becomes essential to address these issues through efficient management and treatment plans, which propels the need for DFU goods and services.

Collaborative Research and Development:

New treatments and interventions for diabetic foot ulcers are being developed as a result of partnerships between pharmaceutical companies, academic institutions, and healthcare providers. These partnerships quicken the tempo of research and development, resulting in the release of novel goods and therapies and the expansion of the market.

Global Diabetic Foot Ulcers Market Restraints

Several factors can act as restraints or challenges for the Diabetic Foot Ulcers Market. These may include:

Expensive Treatment:

Diabetic foot ulcers can be costly to treat because they require ongoing medical consultations, specialist wound care products, and occasionally surgical procedures. Patients may have financial difficulties as a result, especially if their healthcare coverage is limited.

Inadequate Healthcare Infrastructure:

Many areas, particularly in poor nations, lack a sufficient healthcare infrastructure as well as qualified medical personnel with diabetes foot ulcer management training. Delays in diagnosis, insufficient care, and unfavorable patient outcomes may result from this.

Poor Patient Compliance:

Strict adherence to treatment regimens, which include wound care, glucose management, and lifestyle adjustments, is frequently necessary for the successful treatment of diabetic foot ulcers. However, adherence may be difficult for certain patients for a variety of reasons, including ignorance, financial difficulties, or psychological obstacles.

Growing Prevalence of Diabetes:

Diabetes is becoming more commonplace worldwide, which increases the risk of developing diabetic foot ulcers. This puts a heavy load on healthcare systems, making resource shortages worse and raising the need for treatments for diabetic foot ulcers.

Complications:

Lower limb amputation, gangrene, and infection are among the serious consequences that diabetic foot ulcers can lead to. These issues have a substantial negative influence on patients' quality of life in addition to raising healthcare expenses.

Regulatory Challenges:

Long and expensive regulatory approval procedures may impede the development and implementation of novel therapies for diabetic foot ulcers. Strict regulatory regulations could be a problem for businesses looking to launch novel treatments.

Competitive Environment:

A number of businesses are providing a variety of goods and treatments in the fiercely competitive diabetic foot ulcer market. Competitive pricing can reduce profit margins and pricing power, particularly for businesses offering new treatment choices.

Global Diabetic Foot Ulcers Market Segmentation Analysis

The Global Diabetic Foot Ulcers Market is Segmented on the basis of Type of Treatment, Devices, End-users, and Geography.

Diabetic Foot Ulcers Market, By Type of Treatment

Topical Medications:
Includes creams, ointments, and gels applied directly to the ulcer site to promote healing and prevent infection.
Advanced Wound Care Products:
This segment involves specialized dressings, bandages, and wound care devices designed to accelerate healing and maintain a moist wound environment.
Biologics:
Utilizes biological substances such as growth factors, skin substitutes, and stem cell therapy to stimulate tissue regeneration and wound closure.
Hyperbaric Oxygen Therapy (HBOT):
Involves administering oxygen at increased atmospheric pressure to enhance tissue oxygenation and promote healing in non-healing ulcers.

Diabetic Foot Ulcers Market, By Devices

Pressure Relief Devices:
Includes custom orthotics, offloading shoes, and diabetic foot braces aimed at reducing pressure on ulcer-prone areas of the foot.
Wound Debridement Devices:
Instruments and tools used to remove dead or infected tissue from the wound site to facilitate healing.
Negative Pressure Wound Therapy (NPWT):
Involves applying negative pressure to the wound bed through a vacuum system to promote healing and reduce wound size.
Electrical Stimulation Devices:
Utilizes electrical currents to stimulate wound healing and improve blood flow to the affected area.

Diabetic Foot Ulcers Market, By End-users

Hospitals and Clinics:
Facilities providing inpatient and outpatient care for diabetic foot ulcer patients, including wound care clinics and specialized diabetic foot care centers.
Homecare Settings:
Includes products and services tailored for home use, such as self-administered wound care kits and telemedicine consultations.
Research and Academic Institutes:
Institutions engaged in clinical research, development of novel therapies, and academic training related to diabetic foot ulcers.

Diabetic Foot Ulcers Market, By Geography

North America:
Leading region in terms of market share due to high prevalence of diabetes and advanced healthcare infrastructure.
Europe:
Significant market share attributed to increasing diabetic population and growing adoption of advanced wound care products.
Asia-Pacific:
Emerging market with rising diabetes prevalence and improving access to healthcare services driving market growth.
Latin America:
Increasing awareness about diabetic foot care and improving healthcare facilities contributing to market expansion.
Middle East and Africa:
Growing diabetic population and rising healthcare expenditure driving demand for diabetic foot ulcer treatment options.

Key Players

The major players in the Diabetic Foot Ulcers Market are:

3M Co

Smith & Nephew Plc
B. Braun SE
Molnlycke Health Care AB
MiMedx Group Inc
URGO MEDICAL Australia Pty Ltd
Organogenesis Inc

1 INTRODUCTION OF GLOBAL DIABETIC FOOT ULCERS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DIABETIC FOOT ULCERS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL DIABETIC FOOT ULCERS MARKET, BY TYPE OF TREATMENT

5.1 TOPICAL MEDICATIONS
5.2 ADVANCED WOUND CARE PRODUCTS
5.3 BIOLOGICS
5.4 HYPERBARIC OXYGEN THERAPY (HBOT)

6 GLOBAL DIABETIC FOOT ULCERS MARKET, BY DEVICES

6.1 PRESSURE RELIEF DEVICES
6.2 WOUND DEBRIDEMENT DEVICES
6.3 NEGATIVE PRESSURE WOUND THERAPY (NPWT)
6.4 ELECTRICAL STIMULATION DEVICES

7. GLOBAL DIABETIC FOOT ULCERS MARKET, BY END-USERS

7.1 HOSPITALS AND CLINICS
7.2 HOMECARE SETTINGS
7.3 RESEARCH AND ACADEMIC INSTITUTES

8 GLOBAL DIABETIC FOOT ULCERS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL DIABETIC FOOT ULCERS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Acelity L.P. Inc.
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 B. Braun Melsungen AG
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 BSN Medical GMBH
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Coloplast A/S
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 ConvaTec, Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Medline Industries, Inc.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Medtronic Plc.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Molnlycke Health Care AB
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Organogenesis, Inc.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Smith & Nephew Plc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments